Abiraterone's efficacy confirmed; time to aim higher
Mené sur 1 088 patients atteints d'un cancer de la prostate résistant à la castration de stade métastatique, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'abiratérone en complément de la prednisone (durée médiane de suivi : 49,2 mois)
In The Lancet Oncology, Charles Ryan and colleagues report the final analysis of overall survival from COU-AA-302, a randomised phase 3 trial of abiraterone and prednisone versus placebo plus prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer. Although improvements in radiographic progression-free survival were previously reported from this trial and those data were sufficient for regulatory approval by several agencies, this confirmation of improved survival reaffirms the importance of secondary androgen biosynthesis inhibition (via CYP17 with abiraterone) in metastatic castration-resistant prostate cancer.
The Lancet Oncology , commentaire, 2014